We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-9.98%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.17B
AUM Growth
-$1.61B
Cap. Flow
-$473M
Cap. Flow %
-7.66%
Top 10 Hldgs %
32.27%
Holding
171
New
12
Increased
33
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$89.7M
2
PFE icon
Pfizer
PFE
+$66.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$65.8M
4
ARGX icon
argenx
ARGX
+$49.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$47.1M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$136M
2
BMY icon
Bristol-Myers Squibb
BMY
+$116M
3
HCA icon
HCA Healthcare
HCA
+$100M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$82.9M
5
SVA
Sinovac Biotech, Ltd
SVA
+$72.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPSC icon
151
Century Therapeutics
IPSC
$361M
– –
-307,047
Closed -$4.87M
LAB icon
152
Standard BioTools
LAB
$316M
– –
-3,819,348
Closed -$15M
MRK icon
153
Merck
MRK
$324B
– –
-1,779,300
Closed -$136M
NAUT icon
154
Nautilus Biotechnolgy
NAUT
$149M
– –
-1,452,774
Closed -$7.53M
NRIX icon
155
Nurix Therapeutics
NRIX
$2.46B
– –
-184,468
Closed -$5.34M
NTLA icon
156
Intellia Therapeutics
NTLA
$1.49B
– –
-53,200
Closed -$6.29M
OBIO icon
157
Orchestra BioMed
OBIO
$234M
– –
-500,000
Closed -$5.04M
SEM
158
DELISTED
Select Medical
SEM
– –
-2,289,562
Closed -$36.3M
ZBH icon
159
Zimmer Biomet
ZBH
$18.7B
– –
-581,229
Closed -$71.7M
WHWK
160
Whitehawk Therapeutics
WHWK
$177M
– –
-127,600
Closed -$3.08M
SYRS
161
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-183,750
Closed -$5.99M
AUGX
162
DELISTED
Augmedix, Inc. Common Stock
AUGX
– –
-88,363
Closed -$278K
IMGN
163
DELISTED
Immunogen Inc
IMGN
– –
-3,868,786
Closed -$28.7M
SURF
164
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-467,945
Closed -$2.24M
RXDX
165
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-250,000
Closed -$9.88M
OSH
166
DELISTED
Oak Street Health, Inc.
OSH
– –
-1,290,300
Closed -$42.8M
SVA
167
DELISTED
Sinovac Biotech, Ltd
SVA
– –
-2,839,500
Closed -$72.7M
3 4 5 6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2022 Portfolio in Review

As of Q1 2022, OrbiMed held 171 positions worth $6.17B, down 21% from $7.78B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $473M in Q1 2022, closing 28 positions and reducing 25 holdings. Its most notable exit was Merck, an estimated $136M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, OrbiMed opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $85.3M.

  • OrbiMed's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 719,034 shares worth $85.3M.
  • OrbiMed added most to Pfizer in Q1 2022, an estimated $66.9M increase.
  • OrbiMed's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $116M.
  • OrbiMed fully exited Merck in Q1 2022, selling an estimated $136M.
  • OrbiMed's ten largest holdings make up 32% of its $6.17B portfolio in Q1 2022.
  • OrbiMed opened 12 new positions and closed 28 in Q1 2022.
  • OrbiMed's portfolio value fell 21% quarter-over-quarter to $6.17B.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.